Medicare Advantage faces first enrollment decline in a decade—are UnitedHealth and Humana ready?

UnitedHealth Group (NASDAQ: UNH) and Humana Inc. (NYSE: HUM), two of the largest players in the American health insurance sector, face a turning point in their Medicare Advantage businesses. For the first time in over a decade, the Centers for Medicare & Medicaid Services (CMS) projects a decline in enrollment for the government-backed private insurance program. Enrollment is expected to drop from 34.9 million beneficiaries in 2025 to 34.0 million in 2026. That reduction of nearly 3 percent may appear modest, but the implications for insurer revenue, beneficiary choice, and investor confidence are far more significant.

This projected contraction disrupts one of the most consistent growth engines in U.S. health insurance. For years, Medicare Advantage attracted seniors by offering additional benefits compared with traditional Medicare, while providing insurers with predictable federal reimbursements and quality bonuses. Now, with utilization costs rising, star ratings under pressure, and regulators tightening payment formulas, the growth era may be giving way to recalibration.

Why is Medicare Advantage enrollment expected to shrink in 2026 despite a history of rapid expansion?

Medicare Advantage has been on a near two-decade tear. In 2007, just 19 percent of Medicare beneficiaries were enrolled in private plans. By 2025, that figure had climbed to over 54 percent, representing more than half of America’s seniors. For insurers, this growth translated into billions of dollars in recurring premiums and a relatively stable pool of members. Yet the trend is showing cracks.

One major factor is rising medical costs. Insurers such as UnitedHealth underestimated post-pandemic utilization trends. Hospitalizations, outpatient visits, and chronic condition treatments rose sharply, outpacing the assumptions built into premium pricing. When medical loss ratios climb beyond projections, profitability evaporates. That miscalculation has already forced earnings downgrades. In early 2025, UnitedHealth reported a first-quarter spike in Medicare Advantage care use that sent its stock tumbling in one of its worst trading days in decades.

Another driver is benefit reduction. To preserve margins, insurers are trimming popular supplemental perks like dental, vision, transportation, and wellness programs. Seniors who initially switched to Medicare Advantage for these extras may feel shortchanged. In addition, some insurers are exiting unprofitable markets entirely, reducing choices for beneficiaries in rural or high-cost regions.

Regulatory recalibration is also at play. CMS has been realigning Medicare Advantage payment rates closer to traditional Medicare. For 2026, CMS projects average plan premiums will decline from $16.40 to $14.00, signaling affordability for beneficiaries but constraining insurers’ pricing power. Risk adjustment and star rating methodologies are also being tightened, reducing opportunities for plans to profit from coding intensity or broad quality bonuses.

Finally, quality ratings themselves are under pressure. Star ratings determine whether plans receive bonus payments. Several insurers have already seen rating downgrades, which directly affect revenue and enrollment appeal. When Humana experienced a one-star drop in one of its flagship plans, enrollment dipped noticeably. A sustained pattern of lower ratings could compound financial stress.

How are UnitedHealth and Humana positioned in light of the projected decline in Medicare Advantage?

UnitedHealth Group holds roughly 29 percent of the Medicare Advantage market, with close to 10 million members in 2025. Humana controls around 17 percent, giving the two companies nearly half of all enrollments combined. That concentration means their fortunes are tightly bound to the program’s trajectory.

For UnitedHealth, the enrollment outlook is a double-edged sword. On the one hand, cost overruns and utilization spikes have forced the company to trim its 2025 guidance, rattling investors. On the other hand, UnitedHealth recently announced that nearly 78 percent of its members are expected to remain in four-star or higher-rated plans in 2026. That quality performance reassured markets, pushing shares up more than 3 percent on the news. Investors interpreted the strong star ratings as evidence that the insurer can continue to secure federal bonus payments and maintain competitiveness, even in a tougher environment.

Humana has experienced similar pressures but responded with tighter execution. The company initially forecast a drop of around 550,000 members in 2025. It later narrowed that decline to roughly 500,000 and raised its revenue guidance above $128 billion. The announcement was received positively by markets, with the stock gaining ground as analysts praised Humana’s integrated care strategy and cost discipline. The company’s CenterWell division, which includes primary care and home health, has provided diversification at a time when core insurance profits are under scrutiny.

Institutional investors have adjusted their exposure accordingly. Flows into Humana have been steadier, while UnitedHealth’s volatility has spiked on earnings surprises. Analysts broadly see Humana as the more insulated of the two, though both remain vulnerable if the enrollment downturn deepens.

What does the Medicare Advantage slowdown mean for beneficiaries in 2026?

For seniors, the projected decline in Medicare Advantage enrollment is not simply a matter of aggregate statistics. It translates into real-world changes in coverage, costs, and choices.

Fewer plan options in certain geographies will be a key issue. While CMS reassures that 99 percent of beneficiaries will still have access to at least one plan and 97 percent will have access to ten or more, regional disparities may widen. Rural seniors or those in high-cost states may face fewer choices or narrower provider networks.

Supplemental benefits, a hallmark of Medicare Advantage, are also under pressure. Reductions in dental, vision, transportation, or fitness programs may erode the appeal of plans, especially for beneficiaries who valued those extras. Out-of-pocket expenses are subtly shifting as well. While the maximum in-network out-of-pocket limit will fall slightly from $9,350 in 2025 to $9,250 in 2026, that figure masks the fact that cuts to supplemental benefits could increase real out-of-pocket costs for many enrollees.

Premium trends also present a mixed picture. While Medicare Advantage premiums are projected to fall to an average of $14.00, Medicare Part B premiums will rise from $185 in 2025 to $206.50 in 2026. For seniors balancing fixed incomes, these adjustments may not feel like a net saving.

Beneficiaries will need to pay closer attention during the annual open enrollment period. The Annual Notice of Change documents, mailed each fall, will reveal whether their plan is being discontinued or materially altered. Failing to review and act could result in unexpected coverage changes or higher costs in the following year.

How are markets and policymakers likely to respond to the Medicare Advantage enrollment contraction?

Investors see the 2026 projections as a test of the durability of the Medicare Advantage model. For insurers, the message is clear: manage medical costs with precision or face margin erosion. Some may pursue narrower networks, more aggressive utilization controls, or targeted geographic strategies to protect profitability. Mergers and acquisitions in the sector may also accelerate, as scale becomes more vital in weathering financial stress.

From a policy perspective, CMS has signaled a willingness to maintain broad access while ensuring fiscal sustainability. Policymakers could adjust benchmarks, ease certain benefit requirements, or provide transitional support in markets affected by exits. However, the agency remains committed to curbing excessive federal spending on Medicare Advantage, meaning insurers should not expect a return to the generous reimbursement spreads of the past decade.

What is the long-term outlook for Medicare Advantage beyond 2026?

The decline projected for 2026 may not represent the end of Medicare Advantage’s dominance but rather a pause in its trajectory. CMS itself has noted that actual enrollment historically outpaces insurer projections. Seniors continue to prefer the program’s integrated benefits compared with traditional Medicare, and the private sector remains eager to serve this market.

Yet the era of unchecked growth is likely over. Instead, the next phase will be characterized by careful cost management, regulatory compliance, and selective expansion. For insurers, that means refining their underwriting models, investing in quality improvement to preserve star ratings, and diversifying revenue streams. For investors, it suggests a more cautious approach to valuations, factoring in potential volatility rather than assuming steady double-digit growth.

The Medicare Advantage story is thus at an inflection point. Insurers must adapt to tighter margins, beneficiaries must remain vigilant about coverage changes, and investors must recalibrate expectations. The program that once seemed an unstoppable growth engine is now confronting the realities of cost, policy, and demographic pressures. How insurers and policymakers respond will determine whether 2026 marks a temporary slowdown or the beginning of a more fundamental shift in the American health insurance landscape.